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BACKGROUND: No reliable prognostic markers exist for squamous cell carcinoma of the tongue, and its prognosis can even in early
stages be unpredictable and survival poor despite treatment. A potential marker is oncoprotein cancerous inhibitor of PP2A (CIP2A),
which acts as a prognostic marker in gastric and non-small cell lung cancers.
METHODS: We collected specimens of 73 stage T1N0M0 and T2N0M0 oral squamous cell carcinomas of the tongue, as well as
samples from normal oral mucosa, dysplastic lesions, and invasive carcinomas (n¼39). All samples were stained for CIP2A by
immunohistochemistry. Survival curves were constructed according to the Kaplan–Meier method. The Cox proportional hazard
model served for univariate and multivariate survival analysis.
RESULTS: High CIP2A immunoreactivity predicted poor survival in tongue cancer patients (P¼0.027, logrank test). In multivariate
survival analysis, CIP2A was an independent prognostic factor (HR 2.02, 95% confidence interval 1.07–3.82, P¼0.030). Cytoplasmic
CIP2A expression was higher in severe dysplasia than in mild dysplasia.
CONCLUSION: Our results suggest that high CIP2A expression characterises aggressive disease. Acting as a prognostic marker it might
be of help when choosing patients for adjuvant treatment in tongue cancer patients.
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Oral squamous cell carcinoma, the most common cancer of the
head and neck region, has, globally, a greatly varying incidence
depending on geographical area and prevalent risk factors (Barnes
et al, 2005; Curado et al, 2008). The increasing incidence of oral
cancer is largely explained by a rise in tobacco or alcohol
consumption, or both (Blot et al, 1988). Tongue cancer can be
associated with an unpredictable prognosis and poor survival
despite treatment (Bello et al, 2010a,b). Its most important
prognostic factors are tumour size, nodal involvement, and depth
of infiltration, but the results concerning histological grade vary
(Woolgar, 2006). Better prognostic markers are still needed, as
survival for patients with the same clinicopathological stage varies
considerably.
Cancerous inhibitor of PP2A (CIP2A) is an oncoprotein
expressed in several cancers, among them head and neck (Junttila
et al, 2007). It has a prognostic role in gastric and non-small cell
lung cancers (Khanna et al, 2009; Dong et al, 2011); in addition,
it is abundantly expressed in oral dysplastic and malignant tissues
(Katz et al, 2010).
In tongue cancer, what is of particular importance is to predict
relative risk for an individual patient in order to separate out those
at high risk for recurrence to receive adjuvant treatment. This
is especially demanding, as even small tumours occasionally
metastasise (Keski-Sa ¨ntti et al, 2007). On this basis, we studied the
prognostic role of CIP2A expression in a series of early-stage
(T1N0M0 and T2N0M0) oral tongue squamous cell carcinomas.
PATIENTS AND METHODS
Patients
We collected retrospectively 73 consecutive patients, preopera-
tively staged as T1N0M0 and T2N0M0 tumours, treated with
curative intent for oral squamous cell carcinoma of the tongue.
Treatment was given between 1992 and 2002 at the Helsinki
University Central Hospital according to the guidelines of the
tumour board meeting. The patient material has been described in
detail by Keski-Sa ¨ntti et al (2006, 2007). In brief, 36 men and 37
women were included, median age was 59 years (range 23–95).
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sInitially, 35 (48%) tumours were classified as T1, and 38 (52%)
as T2. Following resection for cure of that primary tumour, 31
patients received no further treatment, whereas 42 underwent
elective neck treatment (neck dissection, 9; neck dissection and
radiotherapy, 32; radiotherapy only, 1). In elective neck dissection,
primary lymph-node positivity (pNþ) was noted in 14. During
follow-up, 10 developed neck recurrence apparently representing
late lymph-node metastases without primary recurrence. Median
follow-up of patients at study end was 7.9 years (range 0.3–17.2).
Five-year overall survival was 68.5% (95% confidence interval (CI)
57.9–79.1). Approval of the study came from the local Ethics
Committee and National Supervisory Authority of Welfare and
Health. Survival data and cause of death were obtained before this
study from patient records, the Population Registry, and Statistics
Finland. All samples were reviewed by an oral pathologist.
Tissue samples
Tumour samples were fixed in formalin, embedded in paraffin,
and stored in the archives of the Department of Pathology,
Helsinki University Central Hospital. Representative areas of each
tumour were chosen from H&E staining of the tumour samples.
Six representative 1mm cores from marked areas were obtained
from each tumour with a tissue microarray instrument (Beecher
Instruments, Silver Spring, MD, USA) as described (Kononen et al,
1998; Kallioniemi et al, 2001; Torhorst et al, 2001). In nine
patients, all array cores were missing or included no tumour tissue.
In seven of these patients, whole sections from the tumour
specimens were stained. Two cases had no representative tissue
available for analysis.
In addition, representative specimens were collected from oral
normal mucosa, dysplastic lesions, and invasive carcinoma
(n¼37).
Immunohistochemistry
For the detailed immunohistochemistry protocol, see Khanna et al
(2009). For antigen retrieval, slides were treated in a PreTreatment
module (Lab Vision Corp., Fremont, CA, USA) in Tris–HCl buffer
(pH 8.5) for 20min at 981C. Staining of sections was performed in
Autostainer 480 (Lab Vision Corp.) using the Dako REAL
EnVision Detection System, Peroxidase/DABþ, Rabbit/Mouse
(Dako, Glostrup, Denmark). A rabbit polyclonal CIP2A antibody
served, at a dilution of 1:3000 for 1h at room temperature, as the
primary antibody (Soo Hoo et al, 2002). The staining protocol for
Ki-67 has been described (Ha ¨yry et al, 2010).
Scoring of immunoreactivity
Tumour specimens were scored independently from whole
sections (hot-spot areas) and tissue microarrays by two research-
ers (CB and JH) blinded to clinical status and outcome data.
Cytoplasmic CIP2A immunopositivity was scored as 0–3 based on
the intensity of cancer-cell immunoreactivity, and the highest
intensity of the six cores was used for further analysis. Negative
immunoreactivity was scored as 0, and diffuse weak cytoplasmic
positivity as 1. Moderately positive or focally strongly positive
intensity was scored as 2, and homogeneously strong intensity as 3.
In normal mucosa, dysplastic lesions, and invasive carcinoma
specimens, cytoplasmic CIP2A immunoreactivity was scored as
described, and nuclear CIP2A immunoreactivity was evaluated for
trend. Specimens with discordant scores underwent re-evaluation
with a multiheaded microscope, and the consensus score served
for further analysis. For survival analysis, we were able to score 71
(97%) patient samples for CIP2A. For statistical analysis, the
patients were divided into two groups: low CIP2A immuno-
reactivity (scores 0–2) and high immunoreactivity (score 3).
Statistical analysis
Associations between CIP2A positivity and clinicopathologic vari-
ables were assessed by the w
2-test. Overall survival was calculated
from date of diagnosis to death, while disease-specific survival was
calculated from date of diagnosis to death from tongue cancer.
Survival curves were constructed according to the Kaplan–Meier
method and compared with the logrank test (SPSS version 17.0 for
Mac; SPSS, Inc., Chicago, IL, USA). For univariate and multivariate
survival analysis, the Cox proportional hazard model had the
following categorical covariates entered in a backward stepwise
manner: tumour size (pT-classification), grade, invasion depth of
the tumour, Ki-67 expression, and CIP2A expression.
RESULTS
Immunohistochemistry and prognosis
Cytoplasmic CIP2A immunoreactivity, tested in 73 cases, was
negative in 2 (2.8%), weakly positive in 9 (12.7%), moderately
positive in 28 (39.4%), and strongly positive in 32 (45.1%) cases.
In the final analysis, negative to moderately positive CIP2A
immunoreactivity (scores 0–2) was regarded as representative of
low expression, whereas strongly positive CIP2A (score 3)
represented high expression. Representative images of immuno-
staining are shown in Figure 1. High cytoplasmic CIP2A
Figure 1 Cytoplasmic CIP2A expression in tongue cancer specimens was scored as (A) negative, (B) moderately positive, and (C) strongly positive.
Original magnification was  200.
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simmunoreactivity was a marker of reduced overall survival with a
5-year survival of 59.4% (95% CI 42.4–76.4) for the patients with
strongly positive CIP2A, compared with 74.4% (95% CI 60.7–88.1)
for those with low CIP2A expression (logrank test, P¼0.027;
Figure 2A). For disease-specific survival, 5-year survival for
patients with strongly positive CIP2A was 71.0% (95% CI 55.0–
87.0) compared with 84.6% (95% CI 73.3–96.0) for patients with
low CIP2A immunoreactivity (logrank test, P¼0.038; Figure 2B).
Association of CIP2A with clinicopathological variables
An association appeared between high CIP2A expression and high
histological tumour grade (P¼0.009), and invasion depth 44mm
(w
2-test, P¼0.041; Table 1). High CIP2A expression also associated
with high proliferation index of the tumour (Ki-67, P¼0.008), but
no association appeared between cytoplasmic CIP2A immuno-
reactivity and age, gender, tumour size (pT-classification), or
lymph-node positivity (pN-classification). We compared the
tumours tendency to develop primary or late lymph-node
metastases (lymph-node positivity in pathological examination
or neck recurrence without a local recurrence) with CIP2A
expression, and found no association between these (P¼0.064).
Univariate and multivariate survival analysis
Univariate survival analysis was performed for clinically important
subgroups of tongue cancer patients. Patients with pT1 tumours
showed no difference in overall survival when the analysis was
stratified according to CIP2A expression (logrank test, P¼0.124;
Table 2; Figure 2C). Among patients with pT2 tumours, however,
5-year survival of CIP2A strongly positive patients was 28.6% (95% CI
0–62.0) compared with 66.7% (95% CI 35.9–97.5) for those with low
CIP2A expression (logrank test, P¼0.018; Figure 2D). In patients
u n d e r6 0a td i a g n o s i s ,C I P 2 Aw a sam a r k e rf o rp o o rp r o g n o s i sw i t ha
5-year survival of 58.8% (95% CI 35.4–82.2) for CIP2A strongly
positive patients compared with 84.2% (95% CI 67.8–100.1) for those
with low CIP2A immunoreactivity (logrank test, P¼0.042; Table 2).
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Figure 2 CIP2A expression and survival in tongue cancer patients. (A) Overall survival analysis according to the Kaplan–Meier method for cytoplasmic
CIP2A immunoreactivity (logrank test, P¼0.027). (B) Disease-specific overall survival analysis for cytoplasmic CIP2A immunoreactivity (logrank test,
P¼0.038). (C) Overall survival analysis stratified for patients with pT1 tumours (logrank test, P¼0.124), and (D) pT2 tumours (logrank test, P¼0.018).
Table 1 Association of CIP2A with clinicopathologic variables in 71






variable nn% n % P-value
a
Age, years
o60 36 19 52.8 17 47.2 0.712
X60 35 20 57.1 15 42.9
Gender
Male 37 18 48.6 19 51.4 0.267
Female 34 21 61.8 13 38.2
Grade
I 23 18 78.3 5 21.7 0.009
II 34 17 50.0 17 50.0
III 14 4 28.6 10 71.4
Tumour size, mm
pT1 (p20) 54 30 55.6 24 44.4 0.961
pT2 (21–40) 16 9 56.3 7 43.8
Node positivity
pN0 26 16 61.5 10 38.5 0.119
pN+ 14 5 35.7 9 64.3
Invasion depth, mm
p4 27 19 70.4 8 29.6 0.041
44 44 20 45.5 24 54.5
Ki-67, %
0–29 13 8 61.5 5 38.5 0.008
30–49 23 18 78.3 5 21.7
50–79 14 6 42.9 8 57.1
X80 16 4 25.0 12 75.0
Abbreviation: CIP2A¼cancerous inhibitor of PP2A.
aw
2-test.
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sIn multivariate survival analysis, age over 60 years (hazard ratio
(HR) 2.18, 95% CI 1.11–4.28, P¼0.023), tumour size 21–40mm
(HR 2.48, 95% CI 1.19–5.17, P¼0.016), and high CIP2A
expression (HR 2.02, 95% CI 1.07–3.82, P¼0.030; Table 3)
remained as independent prognostic factors.
CIP2A expression in oral squamous epithelial lesions
We also studied CIP2A expression in a small series (n¼37) of oral
squamous epithelial lesions. In normal oral mucosa, the epithelium
was negative or weakly positive for cytoplasmic CIP2A in the basal
cell area, whereas nuclei tended to stain homogenously positive
(Table 4; Figure 3A). As a trend, cytoplasmic CIP2A expres-
sion was higher in severe epithelial dysplasia than in mild
dysplasia, compared with nuclear CIP2A, which was low in
severe dysplasia but was expressed to a greater extent in lesions
with mild dysplasia (Figure 3B–D). In invasive carcinomas,
cytoplasmic CIP2A protein expression was either low (Figure 3E)
or high (Figure 3F).
DISCUSSION
No reliable prognostic biomarkers for tongue cancer are in clinical
use. We found here in oral squamous cell carcinoma of the tongue,
high CIP2A expression to predict poor survival, with these
patients’ 5-year overall survival being 59.4% compared with
74.4% for patients with low CIP2A expression. For disease-specific Table 2 Survival analysis according to CIP2A immunoreactivity in









survival 95% CI P-value
a
Age, years
o60 84.2 67.8–100.1 58.8 35.4–82.2 0.042
X60 65.0 44.1–85.9 60.0 35.2–84.8 0.347
Tumour size, mm
pT1 (p20) 76.7 61.5–91.8 66.7 47.8–85.5 0.124
pT2 (21–40) 66.7 35.9–97.5 28.6 0–62.0 0.018
Abbreviations: CIP2A¼cancerous inhibitor of PP2A; CI¼confidence interval.
aLogrank test.
Table 3 Cox regression analysis for overall survival of tongue cancer patients
Univariate survival analysis Multivariate survival analysis
Variable Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age, years
o60 1.00
X60 1.84 0.96–3.45 0.056 2.18 1.11–4.28 0.023
Gender
Male 1.00
Female 0.97 0.52–1.79 0.916
Grade
I 1.00
II 1.95 0.93–4.11 0.079
III 1.88 0.74–4.81 0.185
Tumour size, mm
pT1 (p20) 1.00
pT2 (21–40) 1.10 0.97–3.76 0.062 2.48 1.19–5.17 0.016
Invasion depth, mm
p4 1.00
44 2.20 1.10–4.40 0.025
Ki-67, %
0–29 1.00
30–49 1.30 0.53–3.18 0.561
50–79 1.44 0.52–4.00 0.483
X80 1.23 0.46–3.33 0.682
CIP2A expression
Low 1.00
High 1.99 1.07–3.70 0.030 2.02 1.07–3.82 0.030
Abbreviations: CIP2A¼cancerous inhibitor of PP2A; CI¼confidence interval.
Table 4 Distribution of scores in normal, dysplastic, and invasive
carcinoma specimens (n¼37)
CIP2A cytoplasmic score (n)
Tumour type 0 1 2 3 Total




In situ carcinoma 04408
Microinvasive carcinoma 02204
Squamous cell carcinoma 0163 1 0
Abbreviation: CIP2A¼cancerous inhibitor of PP2A.
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ssurvival – with a 5-year survival of 71.0% vs 84.6% for those with
low CIP2A expression – the result was similar. These results are in
line with previous ones regarding gastric cancer (Khanna et al,
2009), and with findings of Dong et al (2011) on non-small cell
lung cancer.
High CIP2A expression was able to predict poor prognosis
within clinically important subgroups of tongue cancer patients,
such as in pT2 tumours and in young patients. To date, in tongue
cancer, stage is the most common prognostic factor used, but
prognosis varies considerably even among similar tumours; and
hence, we need better prognostic markers to avoid unnecessary
adjuvant treatment for those with a favourable prognosis (Bello
et al, 2010a,b). Our results suggest a role for CIP2A as a prognostic
marker in these pT2 and young patient groups, in which occult
metastases are common despite small tumour size at first
presentation (Keski-Sa ¨ntti et al, 2007).
Junttila et al (2007) have shown that CIP2A promotes early
cellular transformation and malignant growth in head and neck
squamous cell carcinoma cells. We found an association between
high CIP2A expression and high grade, tumour invasion depth
44mm, and high proliferation index. These results indicate that
CIP2A is a marker of aggressive disease, in line with our study on
gastric cancer showing CIP2A expression to associate with high
proliferation index and aneuploidy (Khanna et al, 2009). In breast
cancer, Come et al (2009) showed that high CIP2A expression
associates with high proliferation index, p53 mutation, and high
Scarff–Bloom–Richardson grade. In lung cancer, Dong et al
(2011) demonstrated CIP2A to be an independent prognostic
factor. In our present study we show that CIP2A is an independent
prognostic factor in tongue cancer.
We found no association between CIP2A and cytoplasmic or
nuclear c-Myc immunoexpression in tongue cancer (data not
shown), when we compared CIP2 with cytoplasmic and nuclear
c-Myc immunoreactivity previously described (Ha ¨yry et al, 2010),
in contrast to our results in gastric cancer (Khanna et al, 2009).
In lung cancer, a correlation is detectable between CIP2A and
c-Myc mRNA expression levels (Dong et al, 2011). It is possible
that CIP2A and c-Myc have different expression levels in tongue
cancer than in other cancers studied before.
In hepatocellular carcinoma, CIP2A is found to mediate PP2A-
dependent Akt inactivation (Chen et al, 2010). In preneoplastic
lesions, p-Akt is frequently activated, and it serves as a prognostic
marker for poor disease-free survival in tongue cancer (Massarelli
et al, 2005). The possible route by which CIP2A affects the
aggressiveness and poor outcome in tongue cancer may be through
the Akt signalling pathway. Another possible signalling pathway of
CIP2A influence may be via the death-associated protein kinase
(DAPk) protein. Recently, Guenebeaud et al (2010) discovered that
CIP2A inhibits DAPk-mediated apoptosis and hence, may increase
malignant growth (Gozuacik and Kimchi, 2006). In head and neck
cancer, hypermethylation at the DAP-kinase gene promoter
correlated with advanced disease and lymph-node metastases
(Sanchez-Cespedes et al, 2000).
In comparison with lung and gastric cancers, in tongue cancer
CIP2A expression is more intense. Only two specimens were
scored as completely negative, with 85% of the specimens scored
as moderately or strongly positive (scores 2 and 3). The difference
in level of expression might be due to tongue cancer’s being
an epidermoid cancer, whereas previously studied cancers were
mainly adenocarcinomas (Junttila et al, 2007; Khanna et al, 2009;
Dong et al, 2011). Moreover, in esophageal squamous cell
carcinoma, CIP2A was overexpressed in 90% of the specimens
studied (Qu et al, 2010).
Cancerous inhibitor of PP2A is overexpressed in human oral
dysplasia and carcinoma tissues compared with expression in
normal oral mucosa (Katz et al, 2010). Interestingly, in comparing
severe dysplasia with mild dysplasia, our impression was that a
gradual decrease in the amount of nuclear CIP2A staining and
simultaneously an increasing cytoplasmic staining is seen. The
limited number of specimens, however, did not allow statistical
analysis. The role of nuclear and cytoplasmic CIP2A remains thus
far unresolved. In cancer specimens, however, we noted that
cytoplasmic CIP2A was expressed both at low and at high levels.
Junttila et al (2007) have suggested that CIP2A expression is
already induced in premalignant head and neck squamous cell
carcinoma tissue in response to a combination of oncogenic
Ras signalling with inhibition of the TGF-b tumour suppressor
pathway.
In conclusion, in tongue cancer, high cytoplasmic CIP2A
expression characterises aggressive disease and is an independent
prognostic marker indicating need for adjuvant treatment after
surgery. Our results encourage further validation and quantifica-
tion of the scoring methods, as a step towards developing CIP2A
into a clinically useful biomarker in routine pathology.
*
Figure 3 Characterisation of CIP2A expression during development of oral squamous epithelial dysplasia. (A) Normal oral mucosa with basal cytoplasmic
CIP2A positivity (arrow) serving as a control specimen. (B) Severe dysplasia where nuclear positivity disappears (arrow) in oral buccal mucosa.
(C) Transition area (asterisk) to carcinoma in situ from the anterior palatinal mucosa. (D) Epithelial budding (arrow) in mucosal tissue transforming into
carcinoma. (E) Mild and (F) strong CIP2A immunoexpression in invasive oral squamous cell carcinoma.
CIP2A is a prognostic indicator in tongue cancer
CB o ¨ckelman et al
1894





















CIP2A antibody was a kind gift from Dr Edward K Chan,
University of Florida, USA. We thank Anne Aarnio, Elina Aspiala,
Tuire Koski, and Pa ¨ivi Peltokangas for their excellent technical
assistance. This work was financially supported by Finska
La ¨karesa ¨llskapet (CB and CH), the Finnish Cancer Society (AR),
the Finnish Dentists’ Association Apollonia (JH), Helsinki
University Central Hospital Research Funds (AR and CH), the
Kurt and Doris Palander Foundation (CB), Medicinska under-
sto ¨dsfo ¨reninen Liv och Ha ¨lsa (CH), the Sigrid Juse ´lius Foundation
(AR and CH), Suomalais-Norjalainen La ¨a ¨ketieteen Sa ¨a ¨tio ¨ (LM),
the Waldemar von Frenckell Foundation (CB), and the Weikko
Wilhelm Peltonen Foundation (CB).
REFERENCES
Barnes L, Eveson JW, Reichart P, Sidransky D (eds) (2005) World Health
Organization Classification of Tumours. Pathology and Genetics of Head
and Neck Tumours. IARC Press: Lyon, pp 169–170
Bello IO, Soini Y, Salo T (2010a) Prognostic evaluation of oral tongue
cancer: means, markers and perspectives (I). Oral Oncol 46: 630–635
Bello IO, Soini Y, Salo T (2010b) Prognostic evaluation of oral tongue
cancer: means, markers and perspectives (II). Oral Oncol 46: 636–643
Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-
Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni Jr JF
(1988) Smoking and drinking in relation to oral and pharyngeal cancer.
Cancer Res 48: 3282–3287
Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL
(2010) CIP2A mediates effects of bortezomib on phospho-Akt and
apoptosis in hepatocellular carcinoma cells. Oncogene 29: 6257–6266
Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J,
Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thezenas S, Westermarck J
(2009) CIP2A is associated with human breast cancer aggressivity.
Clin Cancer Res 15: 5092–5100
Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P
(eds) (2008) Cancer Incidence in Five Continents. International Agency
for Research on Cancer: Lyon
Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH (2011)
CIP2A is overexpressed in non-small cell lung cancer and correlates with
poor prognosis. Ann Surg Oncol 18: 857–865
Gozuacik D, Kimchi A (2006) DAPk protein family and cancer. Autophagy
2: 74–79
Guenebeaud C, Goldschneider D, Castets M, Guix C, Chazot G, Delloye-
Bourgeois C, Eisenberg-Lerner A, Shohat G, Zhang M, Laudet V, Kimchi
A, Bernet A, Mehlen P (2010) The dependence receptor UNC5H2/B
triggers apoptosis via PP2A-mediated dephosphorylation of DAP kinase.
Mol Cell 40: 863–876
Ha ¨yry V, Ma ¨kinen LK, Atula T, Sariola H, Ma ¨kitie A, Leivo I, Keski-Sa ¨ntti
H, Lundin J, Haglund C, Hagstro ¨m J (2010) Bmi-1 expression predicts
prognosis in squamous cell carcinoma of the tongue. Br J Cancer 102:
892–897
Junttila MR, Puustinen P, Niemela ¨ M, Ahola R, Arnold H, Bottzauw T,
Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ,
Grenman R, Kast J, Kallunki T, Sears R, Kahari VM, Westermarck J
(2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51–62
Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001) Tissue microarray
technology for high-throughput molecular profiling of cancer. Hum Mol
Genet 10: 657–662
Katz K, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S,
Chan EKL (2010) CIP2A expression and localization in oral carcinoma
and dysplasia. Cancer Biol Ther 10: 694–699
Keski-Sa ¨ntti H, Atula T, Tikka J, Hollmen J, Ma ¨kitie AA, Leivo I (2007)
Predictive value of histopathologic parameters in early squamous cell
carcinoma of oral tongue. Oral Oncol 43: 1007–1013
Keski-Sa ¨ntti H, Atula T, Tornwall J, Koivunen P, Ma ¨kitie A (2006) Elective
neck treatment versus observation in patients with T1/T2 N0 squamous
cell carcinoma of oral tongue. Oral Oncol 42: 96–101
Khanna A, Bo ¨ckelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M,
Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristima ¨ki A
(2009) MYC-dependent regulation and prognostic role of CIP2A in
gastric cancer. J Natl Cancer Inst 101: 793–805
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S,
Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue
microarrays for high-throughput molecular profiling of tumor
specimens. Nat Med 4: 844–847
Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S,
De Placido S, Myers JN, Papadimitrakopoulou VA (2005) Akt activation
correlates with adverse outcome in tongue cancer. Cancer 104: 2430–2436
Qu W, Li W, Wei L, Xing L, Wang X, Yu J (2010) CIP2A is overexpressed in
esophageal squamous cell carcinoma. Med Oncol; e-pub ahead of print
8 December 2010
Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH,
Koch WM, Jen J, Herman JG, Sidransky D (2000) Gene promoter
hypermethylation in tumors and serum of head and neck cancer patients.
Cancer Res 60: 892–895
Soo Hoo L, Zhang JY, Chan EK (2002) Cloning and characterization of a
novel 90kDa ‘companion’ auto-antigen of p62 overexpressed in cancer.
Oncogene 21: 5006–5015
Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F,
Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001)
Tissue microarrays for rapid linking of molecular changes to clinical
endpoints. Am J Pathol 159: 2249–2256
Woolgar JA (2006) Histopathological prognosticators in oral and
oropharyngeal squamous cell carcinoma. Oral Oncol 42: 229–239
CIP2A is a prognostic indicator in tongue cancer
CB o ¨ckelman et al
1895
British Journal of Cancer (2011) 104(12), 1890–1895 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s